10.25384/SAGE.8184704.v1 Meritxell Bellet Meritxell Bellet Faten Ahmad Faten Ahmad Rafael Villanueva Rafael Villanueva Carolina Valdivia Carolina Valdivia Julián Palomino-Doza Julián Palomino-Doza Ada Ruiz Ada Ruiz Xavier Gonzàlez Xavier Gonzàlez Encarna Adrover Encarna Adrover Analía Azaro Analía Azaro Maria Valls-Margarit Maria Valls-Margarit Josep Lluís Parra Josep Lluís Parra Juan Aguilar Juan Aguilar Maria Vidal Maria Vidal Anastasi Martín Anastasi Martín Joaquín Gavilá Joaquín Gavilá Santiago Escrivá-de-Romaní Santiago Escrivá-de-Romaní Antonia Perelló Antonia Perelló Cristina Hernando Cristina Hernando Ainhara Lahuerta Ainhara Lahuerta Pilar Zamora Pilar Zamora Victoria Reyes Victoria Reyes María Alcalde María Alcalde Helena Masanas Helena Masanas Pamela Céliz Pamela Céliz Isabel Ruíz Isabel Ruíz Miguel Gil Miguel Gil Miguel Àngel Seguí Miguel Àngel Seguí Lorena de la Peña Lorena de la Peña InhibCDK-Supplementary_Material_v2_01012019 – Supplemental material for Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication SAGE Journals 2019 CDK inhibitors palbociclib ribociclib breast cancer 2019-05-10 12:00:00 Journal contribution https://sage.figshare.com/articles/journal_contribution/InhibCDK-Supplementary_Material_v2_01012019_Supplemental_material_for_Palbociclib_and_ribociclib_in_breast_cancer_consensus_workshop_on_the_management_of_concomitant_medication/8184704 <p>Supplemental material, InhibCDK-Supplementary_Material_v2_01012019 for Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication by Meritxell Bellet, Faten Ahmad, Rafael Villanueva, Carolina Valdivia, Julián Palomino-Doza, Ada Ruiz, Xavier Gonzàlez, Encarna Adrover, Analía Azaro, Maria Valls-Margarit, Josep Lluís Parra, Juan Aguilar, Maria Vidal, Anastasi Martín, Joaquíín Gavilá, Santiago Escrivá-de-Romaní, Antonia Perelló, Cristina Hernando, Ainhara Lahuerta, Pilar Zamora, Victoria Reyes, María Alcalde, Helena Masanas, Pamela Céliz, Isabel Ruíz, Miguel Gil, Miguel Àngel Seguí and Lorena de la Peña in Therapeutic Advances in Medical Oncology</p>